Ocera Therapeutics fka OCRX

[tedkov]

Ocera Therapeutics Shareholders Upset Over Merger Bid - (via NewsPoints Desk)
November 2, 2017
Tags: NewsPoints Ocera Mallinckrodt United States Corporate Affairs Mergers &Acquisitions

A group of Ocera Therapeutics Inc. shareholders are attempting
to block the $42 million purchase of the company by Mallinckrodt plc.
The shareholders allege that the purchase price of $1.52 per share (approximately $42 million), plus one Contingent Value Right to receive one or more payments in cash of up to $2.58 per share (up to approximately $75 million) based on the successful completion of certain development and sales milestones is insufficient in light of the company's growth prospects and that deal-protection clauses in the merger agreement preclude other
companies from submitting successful competing offers. In addition, shareholders allege that senior management of Ocera Therapeutics obtained personal benefits for their own self interests in agreeing to sell the company at that price that are not being shared with common stockholders.

Ocera Thereapeutics did not immediately respond to requests for a comment.

To contact the law firm on behalf of shareholders of
Ocera Therapeutics for more information call toll free 800.511.7037
or [e-mail]